RussianPatents.com

Agent for treating dugs
IPC classes for russian patent Agent for treating dugs (RU 2423989):
Another patents in same IPC classes:
Method of treating patients with pyoinflammatory skin diseases / 2423976
Invention relates to medicine, namely to surgery and dermatology, more exactly to methods of treating pyoinflammatory diseases of skin, in particular erysipelatous inflammation, furunculosis, acne disease. For this purpose within complex therapy at the background of antibiotics, anti-inflammatory and desensitising medications medication Bestim is introduced for, at least, 5 days. Bestim is introduced per orally in day dose 0.3-1.5 mg during 10 days daily or intramuscularly in physiological solution in day dose 0.1 mg 5 times every second day or for 5 days daily.
Treatment and prevention of benign nevus pigmentosis (nevuses) by means of artemisinin and its derivatives Treatment and prevention of benign nevus pigmentosis (nevuses) by means of artemisinin and its derivatives / 2423974
Invention relates to medicine. Benign nevus pigmentosis of skin can be treated by local application, in particular, external application, of composition of active ingredients of formula (I), where in formula (I) X is CO, CHOZ or CHNRZ, where Z is selected from hydrogen; unbranched or branched (C1-C6) alkyl; unbranched or branched (C2-C6) alkenyl; unbranched or branched (C2-C6) alkinyl, (C3-C8) cycloalkyl; (C6-C24) aryl; (C7-C24) aralkyl; m- and n-CH2(C6H4)COOM; COR3; CSR3; C(NR6)R3; SOR4; SO2OM; SO2NR7R8; SO2O-artemisinyl; SO2NH- artemisinyl; POR4R5 and PSR4R5; where R3 is unbranched or branched (C1-C6) alkyl; unbranched or branched (C2-C6) alkoxy; unbranched or branched (C2-C6) alkenyl; unbranched or branched (C2-C6) alkinyl; (C3-C8) cycloalkyl; (C6-C24) aryl; (C6-C10) aryloxy; (C7-C24) aralkyl; -(CH2)n-COOM, where n it is integer from 1 to 6; or 10α-di-hydro artemisinyl; R4 and R5 are selected independently on each other from unbranched or branched (C1-C6) alkyl; unbranched or branched (C2-C6) alkenyl; unbranched or branched (C2-C6) alkinyl; (C3-C8) cycloalkyl; (C6-C24) aryl; (C7-C24) aralkyl; OM; unbranched or branched (C1-C6) alkoxy; (C6-C10) aryloxy and NR7 R8; R6 are selected from unbranched or branched (C1-C6) alkyl; unbranched or branched (C2-C6) alkenyl; unbranched or branched (C2-C6) alkinyl; (C3-C8) cycloalkyl; (C6-C24) aryl and (C7-C24) aralkyl; M is hydrogen or pharmaceutically acceptable cation; and R7 and R8 are independently on each other hydrogen or unbranched or branched (C1-C6) alkyl, or R7 and R8 together form (C4-C6) alkylene bridge; and R is selected from hydrogen and groups, listed for R6 . These compounds are also effective in prevention of acquired nevuses from nevoid cells.
Method of accelerating healing of skin injuries, caused by denervation and blood supply disturbance Method of accelerating healing of skin injuries, caused by denervation and blood supply disturbance / 2423971
Invention relates to medicine, in particular, to experimental medicine and deals with method of accelerating healing of skin injuries, caused by denervation and blood supply disturbance, which is characterised by introduction of immuno-modulator, and as immuno-modulator applied is tilorone, which in therapeutically effective quantity is introduced externally in form of applications or subcutaneously in form of injections.
Compounds and compositions - hedgehog signalling pathway modulators Compounds and compositions - hedgehog signalling pathway modulators / 2423354
Present invention refers to a compound of formula I ; or to its pharmaceutically acceptable salts where n represents 0, 1 or 2; Y1 represents a bond or a group C(O); Y2, represents a bond, the groups C(O) or S(O)2; R1 represents hydrogen, halogen, cyano, C1-2alkyl; R2 represents hydrogen, halogen, cyano, C1-4alkyl, C1-3alkoxy, halogen-substituted-C1-3alkyl, halogen-substituted-C1-3alkoxyl, C6aryl-C0alkyl, tetrazolyl, C3-6cycloalkyl-C0alkyl, C6-7heterocycloalkyl-C0-4alkyl where 1 or 2 carbon atoms in the ring are substituted by the groups selected from -O-, -NH-, -S(O) and -SO2-; and phenoxy groups; where said aryl and heterocycloalkyl groups R2 can be substituted by 1 or 2 radicals independently selected from C1-6alkyl; R3 represents hydrogen, halogen, cyano, C1-3alkoxy or halogen-substituted-C1-2alkyl group and a group -NR6aR6b where R6a and R6b are independently selected from hydrogen and C1-4alkyl; R4 represents hydrogen, halogen, cyano, C1-3alkoxy or halogen-substituted-C1-2alkyl group; R5 represents hydrogen or C1-3alkyl group; L represents a bivalent radical selected from ; ; ; ; ; ; ; ; ; ; ; ; and ; where asterisks the junctions of Y2 and R2; where any bivalent radical L can be substituted by 1 or 2 radicals independently selected from halogen, hydroxy, cyano, C1-4alkyl, C1-4alkyl carbonylamino, C1-4alkoxy, C1-4alkoxycarbonyl, halogen-substituted - C1-4alkyl, C1-3alkylsulfonyl, C1-3alkylsulfonyl-amino, cyano-substituted - C1-4alkyl and halogen-substituted -C1-4alkoxy radicals. Also, the invention refers to a method of Hedgehog path inhibition in a cell and to a method of undesired cell proliferation inhibition which involves the interaction of the compound of formula I and the cell.
Composition containing actinidia and methods of their application Composition containing actinidia and methods of their application / 2423139
Claimed group of inventions relates to medicine. Claimed are methods of immune response regulation and reduction of inflammatory symptoms in mammal, with atopic dermatitis. For this purpose introduced is, at least, one medication of frost-resistant plant kiwi and, at least, one corticosteroid. In regulation of immune response in case of atopic dermatitis included is the following treatment period, during which carried out is monotherapy by medication of frost-resistant kiwi without introduction of corticosteroids. Also claimed is composition, which contains, at least, one medication of frost-resistant kiwi and, at least, one corticosteroid. Also claimed is product in form of animal forage, which contains claimed composition. Claimed group of inventions insure efficient regulation of immune response and reduction of inflammatory symptoms in case of atopic dermatitis due to synergetic effect of combination of medications of frost-resistant kiwi and corticosteroids, which makes it possible to reduce need in additional application of corticosteroids in treatment of said pathology and in future carry out monotherapy by medication of frost-resistant kiwi without reduction of treatment efficiency.
Nanoparticles of heterocrystalline mineral for application as medication Nanoparticles of heterocrystalline mineral for application as medication / 2423134
Invention relates to medication for treatment of infectious disease, cancer treatment, wound healing and/or detoxification of subject, which contains nanoparticles of heterocrystalline mineral selected from group of heterocrystalline minerals SiO2, quartzite, grothite, leucoxene and rutilated quartz. Nanoparticles of said minerals have sizes from 0.5 to 200 nm, have ability to desorption in water, can be transported into cell by DNA molecule and can be applied together with anti-metabolic anti-tumour medication.
Method of treating trophic ulcers / 2423118
Invention relates to medicine, in particular to conservative surgery, and can be used for treatment of trophic ulcers. For this purpose, introduced are subtilisin-based medication, neurometabolic protector and antibacterial medication with simultaneous cleaning of ulcer from purulo-necrotic coat with 3% solution of hydrogen peroxide and application of bandage based on Hydrofibre and silver ions on ulcer surface, after appearance of granulations applied is medication based on bioplastic collagen material until complete healing of ulcer defect takes place.
2-amino-4-phenylazoline derivatives and use thereof as hsp90 modulators 2-amino-4-phenylazoline derivatives and use thereof as hsp90 modulators / 2421449
Invention relates to novel compounds of formula I, which are HSP90 (heat-shock proteins) inhibitors and can be used to prepare a medicinal agent for treating tumorous diseases affected by HSP90 inhibition. In formula I R1 denotes Hal, H, OA or A, R2, R3 each independently denotes -O-(X)s-Q, -NHCO-(X)s-Q, -CONH-(X)s-Q, -NH(CO)NH-(X)s-Q, -NH(CO)O-(X)s-Q, -NHSOr(X)s-Q, NHCOA, Hal, Het or H, where, if R2=H, then R3≠H, or if R3=H, then R2≠H, R4 denotes H, R5 denotes H, Hal, A, OA, (CH2)nCOOH, (CH2)nCOOA, O(CH2)oCONH2, NHCOOA, NHCO(CH2)nNH2, NHCONHA or O(CH2)oHet1, A denotes a straight or branched alkyl containing 1-10 carbon atoms, in which 1-5 hydrogen atoms may be substituted with F, Cl and/or Br, X denotes a straight or branched C1-C10 alkylene which is unsubstituted or substituted once, twice or thrice by A, O A, OH, Hal, CN, COOH, COOA, CONH2, NH2, NHCOA, NHCOOA, Q denotes H, Ar or Het, Ar denotes phenyl which is unsubstituted or substituted once, twice or thrice with A, OA, OH, NO2, Hal, CN, (CH2)nCOOH, (CH2)nCOOA and/or tetrazole, Het denotes a cyclic saturated or aromatic 5-6-member heterocycle containing 1-2 N and/or O atoms, optionally condensed with a benzene ring which may be substituted once, twice or thrice with A, OA, OH and/or =O (carbonyl oxygen), Het1 denotes a monocyclic saturated, unsaturated or aromatic heterocycle containing 1-2 N and/or O atoms, which may be mono- or disubstituted with A, OA, OH, Hal and/or =O (carbonyl oxygen), Hal denotes F, Cl, Br or I, n equals , 1, 2, 3 or 4, o equals 1, 2 or 3, s equals 0, 1 or 2.
2-amino-4-phenylazoline derivatives and use thereof as hsp90 modulators 2-amino-4-phenylazoline derivatives and use thereof as hsp90 modulators / 2421449
Invention relates to novel compounds of formula I, which are HSP90 (heat-shock proteins) inhibitors and can be used to prepare a medicinal agent for treating tumorous diseases affected by HSP90 inhibition. In formula I R1 denotes Hal, H, OA or A, R2, R3 each independently denotes -O-(X)s-Q, -NHCO-(X)s-Q, -CONH-(X)s-Q, -NH(CO)NH-(X)s-Q, -NH(CO)O-(X)s-Q, -NHSOr(X)s-Q, NHCOA, Hal, Het or H, where, if R2=H, then R3≠H, or if R3=H, then R2≠H, R4 denotes H, R5 denotes H, Hal, A, OA, (CH2)nCOOH, (CH2)nCOOA, O(CH2)oCONH2, NHCOOA, NHCO(CH2)nNH2, NHCONHA or O(CH2)oHet1, A denotes a straight or branched alkyl containing 1-10 carbon atoms, in which 1-5 hydrogen atoms may be substituted with F, Cl and/or Br, X denotes a straight or branched C1-C10 alkylene which is unsubstituted or substituted once, twice or thrice by A, O A, OH, Hal, CN, COOH, COOA, CONH2, NH2, NHCOA, NHCOOA, Q denotes H, Ar or Het, Ar denotes phenyl which is unsubstituted or substituted once, twice or thrice with A, OA, OH, NO2, Hal, CN, (CH2)nCOOH, (CH2)nCOOA and/or tetrazole, Het denotes a cyclic saturated or aromatic 5-6-member heterocycle containing 1-2 N and/or O atoms, optionally condensed with a benzene ring which may be substituted once, twice or thrice with A, OA, OH and/or =O (carbonyl oxygen), Het1 denotes a monocyclic saturated, unsaturated or aromatic heterocycle containing 1-2 N and/or O atoms, which may be mono- or disubstituted with A, OA, OH, Hal and/or =O (carbonyl oxygen), Hal denotes F, Cl, Br or I, n equals , 1, 2, 3 or 4, o equals 1, 2 or 3, s equals 0, 1 or 2.
Protein kinase c inhibitors Protein kinase c inhibitors / 2421219
Present invention refers to medicine, namely to a new application of common indole derivatives for preparing a drug exhibiting the properties of a protein kinase C inhibitor. A preferential indole derivative is 1-methyl-2-phenylthiomethyl-3-carbethoxy-4-dimethylaminomethyl-5-oxy-6-bromindole hydrochloride.
Method of treating chronic recurrent vulvovaginitis / 2423978
Invention relates to medicine, namely to dermato-venerology and gynecology, and can be applied for treatment of chronic recurrent candidal vulvovaginitis. For this purpose together with antifungal medications inside prescribed is antihistaminic medication erius in day dose 5 mg for 10 days. Then, monthly 5 days before menstruation and during 5 days after it. After that, in pills in day dose 5 mg inside for 6 months.
Method of childbirth induction on gestation term 22-27 weeks in case of pouring out of amniotic fluid / 2423973
Invention relates to medicine, and namely to obstetrics and gynecology, and can be applied for induction of childbirth. For this purpose per orally mifepristone is taken on first day in dose 200 mg three times after every 4 hours. One day after first intake of mifepristone in back fornix of vagina introduced is dinoproston 1 mg.
Medication for treating endometriosis Medication for treating endometriosis / 2423146
Claimed is application of dopamine agonist (for instance, amantadine, bromocriptine, cabergoline, quinagolide, lisuride, pergolide, ropinirole and pramipexole) for production of medication for treatment and prevention of endometriosis.
No donor and dithiolane-containing compositions and their application for improvement of sexual function / 2423120
Invention relates to pharmacology and represents peroral composition, including L-arginine and R-α-lipoic acid in effective amount, where L-arginine is present in molar excess with respect to amount of R-α-lipoic acid present in composition.
No donor and dithiolane-containing compositions and their application for improvement of sexual function / 2423120
Invention relates to pharmacology and represents peroral composition, including L-arginine and R-α-lipoic acid in effective amount, where L-arginine is present in molar excess with respect to amount of R-α-lipoic acid present in composition.
Solid preparative forms of ospemifene Solid preparative forms of ospemifene / 2423113
Invention relates to field of medicine and chemical-pharmaceutical industry, in particular, to solid therapeutic preparative form, which includes granulated materials, containing as therapeutically active compound, ospemifene, also known as (deaminohydroxy)toremifene, or its geometric isomer, stereoisomer, pharmaceutically acceptable salt, ester or metabolite, in combination with one or more intragranular excipients.
Method of choosing therapeutic approach in menstrual disorders in adolescent girls with overweight / 2422824
In adolescent female patients with overweight suffering menstrual disorders of oligomenorrhea or amenorrhea type are examined for a body weight index (BWI) and blood serum leptin level measured by enzyme immunoassay. And if the BWI of the patient exceeds 25.0 kg/m2, and the leptin level is less than 32.52 ng/ml, diet therapy and graduated physical activity are prescribed. The leptin level 32.52 ng/ml and higher in the patient requires additional glucose tolerance test to a common technique to detect insulin resistance. If observing insulin resistance, the complex treatment includes the preparations to provide higher peripheral tissue sensitivity (sensitisers) to insulin. The absence of insulin resistance enables to prescribe the therapy of combined oral contraceptives with drospirenone.
Method of treating nonspecific aerobic vaginitis / 2422147
Claimed is method of treating nonspecific aerobic vaginitis by vagina sanitation with medication "Bioprost" in dose 1 suppository per night for 10 days. Method ensures complex therapeutic effect due to anti-inflammatory action of pumpkin seed oil, improving vigaina microecology, and thymol, which suppresses development of Gram-positive, Gram-negative bacteria, fungi, and possesses activity with respect to protozoa and herpes virus.
Method of treating immune male sterility / 2421220
Invention refers to medicine, namely to andrology and immunology, and can be used for treating immune male sterility caused by autoimmune reactions on own spermatozoa. That is ensured by the intramuscular introduction of 1 % 3-Oxy-6-methyl-2-ethyl-pyridine hydrochloride 3-5 ml daily 2-3 times a day during a follicular cycle phase of a female partner.
Agent for male sexual dysfunction correction / 2421211
Invention refers to medicine, namely to medical rehabilitation, sexology and andrology. For prevention and treatment of male erectile dysfunctions, a topical agent containing a combination of pantohematogen and nitrogen monoxide production inducers. One of the ingredients is a nitrogen monoxide (NO) production inducer that is caused by normal physiology of erection attainment and preservation. A second ingredient of the composition is pantohematogen which represents a native concentrate produced of natural raw materials - blood of antler-producing deer.
Method for prevention of retained placenta in cows / 2416417
Invention relates to veterinary science. The method involves rectal introduction of cooled sapropelic mud.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to agriculture, particularly to veterinary science, and can be used in animal industries for mastitis prevention. An agent for treating dugs containing polyvinyl alcohol, differing by the fact that polyvinyl alcohol grade 11/2 is used, in addition contains 10 % liquid alkaline sapropel hydrolyzate and disinfectant liquid soap "Cleandesin-soft" in the following proportions, wt %: Polyvinyl alcohol grade PVA 11/2 2.0-6.0; 10 % liquid alkaline sapropel hydrolyzate 1-3; "Cleandesin-soft" 0.7-1.0; distilled water - the rest. After application, the agent dries up and forms a thin, strong enough film which is removed after washing the dugs with warm water prior to milking. The agent promotes a soothing effect on dug skin, stimulates wound repair and cracked dug healing and provides an effective mastitis prevention in cows.

EFFECT: agent is easy-to-use and effective, does not require heavy money costs and time expenditures.

1 ex

 

The invention relates to agriculture, in particular animal, and can be used in animal husbandry for the prevention of mastitis. It is known tool for the prevention of mastitis in animals (patent RU 1629064 A1, 12.05.1988, published 22.02.1991,, bull. No. 7, AC 31/14), which consists in the following ratio, wt.%:

Dichloride, bis(N,N-dimethyl-
-N-carbomethoxyamino-N-
-ethylene-ammonium) sulfide 0.5 to 1.5
Glycerin 4,2-4,6
Polyvinyl alcohol : 0,08-0,12
Water Rest

But appearing on the skin film is not sufficiently strong and stable to prevent the penetration of pathogenic microorganisms through the nipple channel.

The aim of the invention is to provide substances which can be applied on oily skin, not draining at the same time, forming a solid, stable film that softens the skin of the nipple, with antimicrobial and wound healing properties.

This objective is achieved in that the tool contains polivinilovy alcohol, forming a film after application and drying, preventing the penetration of the liner channel of pathogenic microflora. Alkaline hydrolysate of sapropel liquid 10%, providing a softening effect on the skin of the teats of the udder, stimulating the healing of wounds and fractures, thereby reducing the risk of mastitis and development of papillomas. As well as liquid soap and disinfectant effect "Clendenin-soft", containing in its composition special water purification, Laureth-2-sulfate sodium, cocamidopropylbetaine, cocamide deja, glycerin, citric acid and hydrogen peroxide, provides antiseptic properties, funds and its ability to stay on untrimmed surfaces in the following ratio, wt.%:

Polyvinyl alcohol varieties 11/2 2,0-6,0
Alkaline hydrolysate of sapropel liquid 10% 1-3
"Clendenin-soft" 0,7-1,0
Distilled water Rest

To obtain the take distilled water in a volume of 800 ml, add 20-60 g of polyvinyl alcohol, and heated with constant stirring to 95°C. until complete dissolution of p is livinallongo alcohol. The resulting composition must be cooled, filtered, add 10-30 ml of the alkaline hydrolysate of sapropel and 7-10 ml "Clendenin-soft", to bring the total solution volume to 1 l and mix. The resulting tool is transparent, has a syrupy consistency, by whipping forms a copious and stable foam. When applied to the skin dries to form a thin, durable enough film, which is removed when you wash the udder before milking, warm water.

Example. Selected group of clinically healthy on mastitis cows. Within two months, every day, after each milking, spent handling the teats of the udder: 150 cows drug prototype (product 1), 1520 cow claimed the drug (2), 150 cows served as controls and no treatments were not exposed (control).

The diagnosis of mastitis was put together with regard to clinical signs and laboratory studies of milk. In group 1 was identified with mastitis 20 animals (which is 13.3%), cracked nipples 24 animals (16,0%). In the 2 group 3 animals with mastitis (2,0%), cracked nipples 7 (4.7 per cent). In group 3 with mastitis 46 animals (30,7%), cracked nipples 33 (22%). Thus, the processing of the claimed product has a softening effect on the skin of the nipple stimulates the healing of wounds and cracked nipples udders and effectively renders prophylactic action mastitis in short the century

The product is easy to use and effective. Its production does not require large monetary and time costs.

Means for processing the teats of the udder containing polyvinyl alcohol, characterized in that the used polyvinyl alcohol brand 11/2 additionally contains an alkaline hydrolysate of sapropel liquid 10%and liquid soap disinfectant effect "Clendenin-soft" in the following ratio, wt.%:

Polyvinyl alcohol varieties 11/2 2,0-6,0
Alkaline hydrolysate of sapropel liquid 10% 1-3
"Clendenin-soft" 0,7-1,0
Distilled water Rest

 
© 2013-2015 Russian business network RussianPatents.com - Special Russian commercial information project for world wide. Foreign filing in English.